Article · 12 Feb 2026
EditorialPublished 2016
Biosimilars: The Road Ahead
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Biosimilars came into existence with the sole ideology of affordable medication for chronic illnesses in the therapy areas of immunology and oncology. The increasingly austere measures and continuous cuts in healthcare budget by many countries forced pharmaceutical companies to develop low cost biologics without compromising on quality. Numerous players have entered this field sensing the wide range of opportunities in multiple therapy areas. The first generation biosimilars emerged, applying the phenomenon of incremental innovation, categorized under hormones (somatropin). Later, the copies of complex mAbs (monoclonal antibodies) were developed. Presently, multiple biosimilars exist for somatropin and epoetin. Recently, the biosimilar of infliximab (Remicade) was approved by the EMA. The Remicade biosimilar, known as Inflectra/Remsima, was jointly developed by Celltroin and Hospira.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Perspective · 29 Dec 2025
Telemedicine in Modern Healthcare: Opportunities, Challenges, and the Road Ahead
Article · 26 Mar 2025
Spinal Cord Injuries: Challenges, Innovations, and the Road Ahead
Commentary · 31 Jan 2025
Climate Overshoot: Risks, Realities, and the Road Ahead
Conference abstract · 18 Nov 2024
The road ahead in pancreatic cancer: Emerging trends and therapeutic prospects
More from this journal
The newest in Insights in Biomedicine.
Article · 20 Mar 2025
The Future of Polyclonal Antibodies: Emerging Technologies and Trends
Article · 31 Dec 2024
Tailored Healthcare: A New Era of Individualized Solutions
Article · 31 Dec 2024
Personalized Medicine: Transforming the Future of Healthcare
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalInsights in Biomedicine
- BylineArticles whose byline prints “Phani Kishore Thimmaraju”
